[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"antibiotic-resistance\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:antibiotic-resistance":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,44,77],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":18,"targetDuration":21,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":29,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100644853","genomic-and-phenotypic-diversity-of-carbapenemase-producing-escherichia-coli-strains-circulating-in-southern-france-100644853",false,"NCT07676513","Genomic and Phenotypic Diversity of Carbapenemase-producing Escherichia Coli Strains Circulating in Southern France.","Genomic and Phenotypic Diversity of Carbapenemase-producing Escherichia Coli Strains Circulating in Southern France. The \"CARBA-COLI\" Study","CARBACOLI","Inclusion Criteria:\n\n* Not applicable to this study of an existing collection of Carbapenemase-producing Enterobacteriaceae strains.\n\nExclusion Criteria:\n\n* Not applicable to this study of an existing collection of Carbapenemase-producing Enterobacteriaceae strains.","ALL",{"count":19,"type":20},163,"ESTIMATED","3 Years","OBSERVATIONAL","Carbapenemase-producing Enterobacteriaceae (CPE) are classified as emerging Highly Resistant Bacteria (eHRB) because they expose infected patients to the risk of treatment failure due to the strains' resistance to last-line β-lactams, carbapenems, and frequent co-resistance to other classes of antibiotics, leading to increased morbidity and mortality. Their high epidemiogenic potential has enabled their global spread. In France, the incidence of Carbapenemase-producing Enterobacteriaceae is rising sharply, both in colonization and in infections. Parallel to this increase, Escherichia coli has become the most common Carbapenemase-producing Enterobacteriaceae (35% of strains in 2024, National Research Committee data), surpassing Klebsiella pneumoniae (24%).\n\nThe investigators hypothesize that the increase in the prevalence of carbapenemase-producing Echerichia coli is associated with a diversification of clones, enzymes, and their variants, and may pose a threefold threat: i) the spread of genes encoding carbapenemases within pathogenic extraintestinal Echerichia coli (ExPEC) pathogroups responsible for urinary tract infections and bacteremias, with a high risk of resistance spreading in the community, ii) the silent spread of Echerichia coli strains producing OXA-48 variants with reduced carbapenem hydrolytic activity, OXA-244 and OXA-484, which are not detected or poorly detected by conventionally used screening media and iii) the emergence of New Dehli Metallo-beta-lactamase (NDM) variants with high hydrolytic activity, such as NDM-5, within Echerichia coli clones possessing Penicillin-Binding Proteins (PLPs) with low affinity for antibiotics, leading to very high-level resistance and a therapeutic dead end in infected patients.",[25,26,27,28],"Antibiotic Resistance","Enterobacteriaceae Infections","Carbapenem-Resistant Enterobacteriaceae Infection","Colonization",[30,27,28,26],"Escherichia coli","NOT_YET_RECRUITING","2026-06-24",{"date":34,"type":35},"2026-06-30","ACTUAL",{"date":37,"type":20},"2026-06-01",{"date":39,"type":20},"2028-06-01",{"name":41,"class":42},"Centre Hospitalier Universitaire de Nīmes","OTHER",1,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":17,"minAge":51,"maxAge":52,"enrollmentInfo":53,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":55,"conditions":56,"keywords":58,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":4},"100631804","characterization-of-the-synergistic-antibacterial-effect-of-verapamil-on-bacterial-isolates-from-cancer-patients-100631804","NCT07505446","Characterization of the Synergistic Antibacterial Effect of Verapamil on Bacterial Isolates From Cancer Patients","Characterization of the Synergistic Antibacterial Effect of Verapamil on Bacterial Isolates From Patients in South Egypt Cancer Institute","Inclusion Criteria:\n\n1. Bacterial isolates from clinical samples submitted for the SECI laboratory for culture and sensitivity testing that are:\n2. MDR: resistant to one or more agent within three or more of antimicrobial classes\n3. XDR: resistant to one or more agent within all but two antimicrobial classes\n4. PDR: resistant to all agents within all antimicrobial classes.\n\nExclusion Criteria:\n\n1. Bacterial isolates from non-cancer patients.\n2. Contaminant or non-pathogenic isolates.\n3. Duplicate isolates from the same patient with identical antibiogram.\n4. Bacterial isolates that are neither MDR, XDR OR PDR.","18 Years","90 Years",{"count":54,"type":20},100,"Multidrug-resistant (MDR) bacteria represent a significant global health challenge, particularly among immunocompromised populations such as cancer patients undergoing chemotherapy. These patients are highly susceptible to severe infections due to weakened immune defenses, often necessitating the use of broad-spectrum or combination antibiotic therapy. Combination regimens may enhance treatment efficacy through synergistic effects, helping to overcome bacterial resistance mechanisms and improve clinical outcomes.\n\nIn recent years, there has been growing interest in the use of non-antibiotic drugs as adjunctive agents to enhance antimicrobial activity. These agents, often referred to as antibiotic adjuvants or resistance modifiers, may improve antibiotic effectiveness through mechanisms such as inhibition of bacterial efflux pumps, disruption of biofilm formation, or interference with resistance pathways.\n\nVerapamil, a widely used calcium channel blocker, has demonstrated potential antimicrobial and resistance-modifying properties. Experimental evidence suggests that verapamil can inhibit bacterial efflux pumps, thereby increasing intracellular concentrations of antibiotics and enhancing their activity against resistant organisms.\n\nThis study aims to evaluate the in vitro synergistic antibacterial activity of verapamil in combination with selected antibiotics against MDR, extensively drug-resistant (XDR), and pandrug-resistant (PDR) bacterial isolates obtained from cancer patients. Standard microbiological methods will be used to determine antimicrobial susceptibility and minimum inhibitory concentrations, while combination effects will be assessed using established synergy testing approaches.\n\nThe findings of this study may contribute to identifying novel, cost-effective strategies to combat antimicrobial resistance through drug repurposing and optimization of existing antibiotic therapies.",[57,25],"Multi Drug Resistant Organisms",[59,60,61,62,63,64,65,66,67],"Verapamil","Antibiotic Adjuvant","Efflux Pump Inhibitor","Antimicrobial Synergy","Checkerboard Assay","Fractional Inhibitory Concentration Index (FICI)","Minimum Inhibitory Concentration (MIC)","MDR \u002F XDR \u002F PDR Bacteria","Cancer Patient Isolates","2026-04-02",{"date":70,"type":35},"2026-04-08",{"date":72,"type":20},"2026-05-01",{"date":74,"type":20},"2027-06-01",{"name":76,"class":42},"Assiut University",{"id":78,"slug":79,"hasResults":11,"nctId":80,"briefTitle":81,"officialTitle":82,"acronym":83,"eligibilityCriteria":84,"healthyVolunteers":11,"sex":17,"minAge":51,"maxAge":4,"enrollmentInfo":85,"targetDuration":4,"studyType":87,"phases":88,"briefSummary":90,"conditions":91,"keywords":95,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":43},"100630311","phase-3-feasibility-of-the-application-of-a-new-six-month-treatment-for-multidrug-resistant-tuberculosis-mdr-tb-patients-in-france-fast-mdr-100630311","NCT07486024","Feasibility of the Application of a New Six-month Treatment for Multidrug-resistant Tuberculosis (MDR-TB) Patients in France (FAST-MDR)","Feasibility of the Application of a New Six-month Treatment for Multidrug-resistant Tuberculosis (MDR-TB) Patients in France - FAST-MDR","FAST-MDR","Inclusion criteria\n\n1. Is 18 years old or more\n2. Is affected by bacteriologically- or molecularly-confirmed tuberculosis, due to strains of M. tuberculosis resistant to rifampicin (with or without resistance to isoniazid) according to a rapid molecular test\n3. Is willing and able to give informed consent to be enrolled in the research project (signed or witnessed consent if the patient is illiterate)\n4. Patients seen in consultation or hospitalized in one of the centers involved for rifampicin-resistant TB, with screening results available and compatible within 14 days following consent signature;\n5. Is willing to use effective\\* contraception: women with childbearing potential\\*\\* must agree to use effective contraception, unless their partner has had a vasectomy, for the duration of study treatment and up to 6 months after the end of study treatment; men who have not had a vasectomy must agree to use effective contraception for the duration of study treatment and up to 3 months after the end of study treatment;\n\n   * The following contraception methods are considered effective, according to local regulation (CTFG recommendations, March 2024):\n\n     1. Combined hormonal contraception (oestrogen + progestin)\n     2. Progestin-only hormonal contraception\n     3. Intrauterine device (IUD)\n     4. Intrauterine hormone-releasing system (IUS)\n     5. Bilateral tubal occlusion\n     6. Vasectomised partner\n\n        * A woman is considered of childbearing potential (WOCBP), i.e. fertile, following menarche and until becoming post-menopausal unless permanently sterile. Permanent sterilisation methods include hysterectomy, bilateral salpingectomy and bilateral oophorectomy. A postmenopausal state is defined as no menses for 12 months without an alternative medical cause. A high follicle stimulating hormone (FSH) level in the postmenopausal range may be used to confirm a post-menopausal state in women not using hormonal contraception or hormonal replacement therapy. However in the absence of 12 months of amenorrhea, a single FSH measurement is insufficient.\n6. Is affiliated to a social security system (as beneficiary) or has state medical aid (AME) or has an ongoing demand for AMEor has an ongoing demand for an emergency medical care (dispositif de soins d'urgence, as applicable for tuberculosis)\n\nExclusion criteria :\n\n1. Is unable to take oral drugs\n2. Has known allergies, hypersensitivity or intolerance or any other medical condition and contra indications to any drug of the regimen\n3. Unwilling to comply to study procedures, at the clinician appreciation\n4. Has proven or likely resistance to bedaquiline, clofazimine, linezolid, pretomanid or moxifloxacine, or has had exposure (for 30 days or more) in past five years to bedaquiline, clofazimine, delamanid, linezolid, or pretomanid\n5. Is taking or needs to take contraindicated medications in association with investigational medicinal products\n6. Has ≥500 msec QTcF interval on any ECG taken at screening or baseline visits, or has any cardiac risk factor for severe arrhythmia\n7. Has severe extrapulmonary TB, including meningo-encephalitis, brain abscess, osteo-arthritis, osteomyelitis\n8. Is concurrently participating in another trial of any medicinal product\n9. Is already on a MDR\u002FRR-TB treatment regimen since 4 weeks or more, and has no need to change the treatment regimen (i.e. adverse events, treatment failure)\n10. Has significant and uncorrectable lab abnormalities at baseline: haemoglobin ≤7.9 g\u002FdL, platelet count \\\u003C75 000\u002Fmm3; absolute neutrophil count \\\u003C1 000\u002F mm3; potassium \\\u003C3.0 mEq\u002FL; serum creatinine \\>3 x upper level of normality (ULN); alanine aminotransferase (ALT) ≥3 x ULN\n11. Has peripheral neuropathy of grade 3 or 4 (CTCAE scale)\n12. Has any other condition (social or medical) which, in the opinion of the site investigator, would make the study participant unsafe\n13. Is known to be pregnant or is unwilling or unable to stop breastfeeding an infant\n14. Individuals permanently legally incompetent adults, under judicial or administrative protection and vulnerable persons",{"count":86,"type":20},55,"INTERVENTIONAL",[89],"PHASE3","The FAST-MDR trial is an externally-controlled, multicentre trial with one prospective arm, evaluating the non-inferiority of the effectiveness of BPaLM in the interventional arm versus the effectiveness of the long, conventional regimen in a French historical cohort of MDR-TB patients (2006-2022). In light of recent WHO recommendations suggesting using BPaLM as a first choice for routine MDR-TB treatment and of the expected benefits of BPaLM over the standard treatment, there will be no internal comparator arm in the study.",[92,93,25,94],"MDR-TB","Tuberculosis Multi Drug Resistant Active","Mycobacterium Tuberculosis",[92,96,97],"BPaLM","Tuberculosis Multi Drug Resistant","2026-03-17",{"date":100,"type":35},"2026-03-20",{"date":102,"type":20},"2026-04",{"date":104,"type":20},"2032-02",{"name":106,"class":42},"Assistance Publique - Hôpitaux de Paris"]